CompletedPhase 3

Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches

123 participantsStarted 2003-12

Plain-language summary

The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the aortic arch and cerebral branches. The results will be compared to the results of MRI taken without Magnevist, and with the results of your X-ray angiography.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Has known or suspected disease of the aortic arch and cerebral branches * Is scheduled for X-ray angiography Exclusion Criteria: * Has any contraindication to magnetic resonance imaging * Is scheduled for any procedure before the X-ray angiography * Had previous bilateral intervention (surgery, bypass) of the arteries of interest

What they're measuring

Accuracy, sensitivity, and specificity based on quantitative assessment of stenosis assesses by blinded reader

Timeframe: Image creation after injection -evaluation at blind read

Trial details

NCT IDNCT00310609

SponsorBayer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Cardiovascular Abnormalities trials